Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.
Oncotarget published "TERT and its binding protein: overexpression of GABPA/B in high grade gliomas" which reported that all GA-binding proteins progress through the glioma grades and have the highest expression levels in secondary glioblastomas.
Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States.
Piperlongumine, a chemical compound found in the Indian Long Pepper plant (Piper longum), is known to kill cancerous cells in many tumor types, including brain tumors.
A micro-sized polymeric net wrapping around brain tumors, just like a fishing net around a shoal of fish: this is the microMESH, a new nanomedicine device capable to conform around the surface of tumor masses and efficiently deliver drugs.
Most people relate cholesterol to heart health, but it is also a critical component in the growth and spread of brain cancer.
With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy, and their combinations.
Scientists at the Fralin Biomedical Research Institute at VTC have identified a new zebrafish model that could help advance glioblastoma multiforme research. Glioblastoma is an aggressive form of primary brain tumor - fewer than one in 20 patients survive five years after diagnosis.
Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year.
A compound found in brown seaweeds could help to treat one of the most common and aggressive forms of malignant brain tumour.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Investigators at Rutgers Cancer Institute of New Jersey have developed a novel approach for utilizing 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes that hold patient tissue samples for rapid programmable drug testing.
Osteosarcoma, a common bone cancer in dogs, affects more than 10,000 dogs in the U.S. each year. While chemotherapy is generally effective at killing some of the cancer cells, the numerous side effects can be painful and often a subset of cancer cells exist that are resistant to chemotherapy.
Glioblastomas are the most common malignant brain tumors in adults. Treatment options are extremely limited and usually not effective, leading to death for most patients within 12-18 months of diagnosis.
An interview discussing the use of spherical nucleic acids (SNAs) and what they show about the importance of structure in pharmaceutical development.
A new machine learning approach classifies a common type of brain tumor into low or high grades with almost 98% accuracy, researchers report in the journal IEEE Access.
Glioblastoma multiforme is an aggressive form of cancer in the brain that is typically fatal. But new findings by VCU Massey Cancer Center and VCU Institute of Molecular Medicine researchers could help increase the effectiveness of the most common current treatments with the addition of lumefantrine, an FDA-approved drug used to treat malaria.
Scientists are developing a combined vaccine to fight the most deadly form of brain cancer.
When you're facing a cancer diagnosis with an average survival span of 12 to 18 months, every milestone is a victory.
Researchers at EMBL's European Bioinformatics Institute and the Francis Crick Institute have analyzed the whole genomes of over 2600 tumors from 38 different cancer types to determine the chronology of genomic changes during cancer development.
Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it.